Rubra Medicaments Ltd. (BSE: 531099) is a Mumbai, Maharashtra-based company in the Health Care Distributors industry. With a market capitalisation of ₹18 Cr, it ranks #4,481 by market cap among the 6,197 Indian listed companies on FinBizNet, and #7 of 11 in Health Care Distributors. At ₹34.99 (as of 16 Nov 2026), the share price is 74.8% below its 52-week high of ₹138.75 and 23.1% above its 52-week low of ₹28.42. The share price is down 53.2% over one year and down 35.9% over three months.
| Current Price | ₹34.99 |
|---|---|
| Market Cap | ₹18 Cr |
| BSE Code | 531099 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors |
| P/E Ratio | 12.2 |
| Return on Equity | 12.67% |
| Return on Assets | 0.83% |
| 52-Week Range | ₹28.42 – ₹138.75 |
| 1-Year Price Change | -53.2% |
| 3-Month Price Change | -35.9% |
| Beta (1Y) | 0.95 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.rubramed.com |
Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Checkpoint Trends Limited engages in the trading business in India. It also provides management and other consultancy services. The company was formerly known as Rubra Medicaments Limited and changed its name to Checkpoint Trends Limited in May 2022. Checkpoint Trends Limited was incorporated in 1991 and is based in Mumbai, India.
1. Pharmaceuticals-This segment engages in the manufacture and sale of pharmaceutical formulations.
1. Tobacco Products-13.3% 2. Fmcg Products-86.7% 3. Unallocable-0%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Trimurthi Ltd | ₹197 Cr | 57.6 | 7.99% | — | +33.3% |
| Achyut Healthcare Ltd | ₹191 Cr | 609.2 | 0.95% | — | +39.7% |
| Vaidya Sane Ayurved Laboratories | ₹148 Cr | — | 13.40% | — | -46.6% |
| Balaxi Pharmaceuticals Ltd | ₹125 Cr | 92.2 | 0.59% | ₹81 Cr | -44.5% |
| Medico Intercontinental Ltd | ₹25 Cr | n/m | -27.14% | ₹14 Cr | -31.5% |
| Zenlabs Ethica Ltd | ₹19 Cr | n/m | -20.44% | — | -12.5% |
| Rubra Medicaments Ltd. | ₹18 Cr | 12.2 | 12.67% | — | -53.2% |
| Nexus Surgical & Medicare Ltd | ₹15 Cr | 20 | 51.41% | — | +76.5% |
| Brawn Biotech Ltd. | ₹7 Cr | 7 | 24.43% | — | +9.4% |
Listed by market capitalisation. Ratios are shown for context only.
Rubra Medicaments Ltd. is trading at ₹34.99, with a market capitalisation of ₹18 Cr.
Rubra Medicaments Ltd. operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors).
Rubra Medicaments Ltd. has a P/E of 12.2 and a return on equity of 12.67%.
Rubra Medicaments Ltd. is listed on the BSE under the scrip code 531099.
Rubra Medicaments Ltd.'s share price is down 53.2% over one year and down 35.9% over three months. Its 52-week range is ₹28.42 to ₹138.75.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.